- Q3 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 14, 2024$1.59 (-2.45%)Earnings
- Q2 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 14, 2023$1.45 (+20.83%)Earnings
- Q1 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2023$2 (-0.99%)Earnings
- Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research TranscriptJul 19, 2023
- Q4 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 07, 2023$2.99 (-1.32%)Earnings
- Immunoprecise Antibodies Ltd at Smallcap Discoveries TranscriptJun 28, 2023
- Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q3 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 16, 2023$3.37 (-10.13%)Earnings
- Q2 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 15, 2022$4.9 (-8.58%)Earnings
- Q1 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2022$4.85 (-9.85%)Earnings
- Q4 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 29, 2022$4.23 (-7.03%)Earnings
- Q2 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 13, 2021$5.06 (-9.96%)Earnings
- Immunoprecise Antibodies Ltd LifeScience Webinar TranscriptApr 28, 2021
Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference Transcript
And welcome to the Jefferies Global Healthcare Conference. My name is Claire, and I am with the investment banking team. And this morning, I am pleased to introduce Jennifer Bath, President and CEO of ImmunoPrecise Antibodies.
And with that, I will hand it off to her.
Great. Thank you, Claire. And thanks, everyone, for joining me today for this presentation. I'm really excited to share with you this presentation about ImmunoPrecise Antibodies, also known as IPA, and also some of the groundbreaking technology at one of our subsidiaries called BioStrand.
What I'm going to share with you today are technologies in artificial intelligence that are solving some of the world's greatest challenges in data analysis and in drug discovery in general. And we'll be providing you with some evidence to demonstrate exactly how we have tackled those particular challenges.
So before I get started, just first of all, our disclaimer that we are operating
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)